Spero Therapeutics, Inc. (SPRO) News

Spero Therapeutics, Inc. (SPRO): $1.21

0.02 (-1.63%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add SPRO to Watchlist
Sign Up

Filter SPRO News Items

SPRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SPRO News Highlights

  • For SPRO, its 30 day story count is now at 6.
  • Over the past 25 days, the trend for SPRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about SPRO are DRUG and RARE.

Latest SPRO News From Around the Web

Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.

Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics Inc

On September 13, 2023, Chief Medical Officer Kamal Hamed sold 39,496 shares of Spero Therapeutics Inc (NASDAQ:SPRO).

Yahoo | September 16, 2023

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer of Sensorium. “He is a seasoned life sciences executive with a track record of success that spans mult

Yahoo | September 12, 2023

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25

Yahoo | September 6, 2023

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on August 25, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 83,000 restricted stock unit awards (RSUs) to t

Yahoo | August 31, 2023

Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | August 29, 2023

Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | August 22, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript August 10, 2023 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.29. Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded and a replay […]

Yahoo | August 13, 2023

Q2 2023 Spero Therapeutics Inc Earnings Call

Q2 2023 Spero Therapeutics Inc Earnings Call

Yahoo | August 11, 2023

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 20.69% and 23.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 10, 2023

Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update

SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and CEO, Effective August 1 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas in

Yahoo | August 10, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!